Patient no.
|
CD3−CD56+
|
CD3+CD56+
|
CD3+CD4+
|
CD3+CD8+
|
NKG2D+ in CD3−CD56+
|
CD16+ in CD3−CD56+
|
CXCR3+ in CD3−CD56+
|
CXCR4+ in CD3−CD56+
|
CX3CR1+ in CD3−CD56+
|
NK activity EC50a
|
---|
1
|
30.18
|
62.53
|
NE
|
NE
|
NE
|
NE
|
NE
|
NE
|
NE
|
2.61
|
2
|
98.41
|
0.93
|
0.40
|
0.24
|
98.91
|
23.01
|
28.33
|
49.79
|
36.79
|
1.31
|
3
|
81.78
|
16.28
|
17.15
|
0.96
|
96.70
|
20.84
|
48.80
|
21.98
|
28.33
|
1.31
|
4
|
98.75
|
0.91
|
0.55
|
0.13
|
96.28
|
29.47
|
36.67
|
29.78
|
28.37
|
1.61
|
5
|
72.84
|
26.50
|
25.49
|
1.87
|
99.59
|
68.39
|
44.82
|
20.32
|
39.51
|
0.63
|
6
|
95.67
|
3.93
|
3.12
|
0.30
|
99.36
|
60.70
|
56.62
|
23.31
|
42.07
|
0.62
|
7
|
86.25
|
13.27
|
3.87
|
0.24
|
95.20
|
50.29
|
29.04
|
31.34
|
26.79
|
1.39
|
8
|
96.60
|
2.27
|
2.25
|
0.07
|
98.54
|
60.46
|
42.90
|
62.89
|
50.40
|
1.24
|
9
|
84.91
|
14.91
|
10.31
|
2.64
|
98.17
|
72.33
|
41.80
|
37.88
|
62.01
|
0.98
|
10
|
65.94
|
38.83
|
33.61
|
0.23
|
98.67
|
62.79
|
44.04
|
42.40
|
51.40
|
1.88
|
11
|
98.49
|
1.39
|
0.45
|
0.11
|
99.45
|
69.23
|
49.69
|
69.29
|
44.33
|
1.76
|
12
|
78.52
|
21.40
|
11.43
|
0.30
|
97.88
|
73.50
|
61.05
|
37.54
|
70.20
|
1.99
|
13
|
97.23
|
2.57
|
2.60
|
0.11
|
99.00
|
32.88
|
57.66
|
49.55
|
54.89
|
0.59
|
14
|
99.45
|
0.44
|
0.28
|
0.09
|
97.82
|
63.59
|
46.12
|
43.73
|
43.15
|
0.39
|
Median (all enrolled patients)
|
90.96
|
8.60
|
3.12
|
0.24
|
98.54
|
60.70
|
44.82
|
37.88
|
43.15
|
1.31
|
Median (ITT population)
|
90.96
|
8.60
|
3.50
|
0.24
|
98.36
|
61.75
|
45.47
|
37.71
|
43.74
|
1.28
|
-
aThe data are presented for EC50, which means the values corresponding to the E:T ratio needed to reduce the cytotoxicity by 50 % from maximum lysis